Hereafter, PI3K/AKT pathway inhibition is regarded as a therapeutic approach [364, 365] followed by the preclinical studies in leukemia cells [366, 367] in spite of the upregulated expression of P2RY14 in acute leukemia cells resistant to PI3K/mTOR inhibition [368]. This evidence concerns the gene PIK3CD and acute leukemia.